top of page
Search

Esketamine Nasal Spray for MDD

In the ceaseless pursuit of unlocking viable treatment options for individuals grappling with Treatment-Resistant Depression (TRD), a recent study presented at Psych Congress 2023 piqued interest in the medical and mental health community. The findings, stemming from the ESCAPE-TRD trial, emphasized the potential economic and therapeutic benefits of esketamine (ketamine in the form of a nasal spray) in comparison to quetiapine extended-release treatment, particularly in the context of work productivity loss (WPL) improvements and associated cost implications.



TRD has many challenges for those directly affected but casts an economic shadow, notably affecting employers in the United States through healthcare costs and impaired work productivity. Esketamine nasal spray has demonstrated a promise in this regard, as outlined in the study, presenting a tangible reduction in WPL and thus suggesting not only a clinical but an economic advantage.


Diligent investigators navigated through an analysis involving participants with major depressive disorder (MDD), who were administered either esketamine nasal spray or quetiapine extended-release treatment in conjunction with specific reuptake inhibitors.


Upon evaluating the findings, a significant decrease in total WPL from baseline was evident in participants administered esketamine nasal spray, alongside weekly cost savings, which showcased a marked disparity when pitted against the alternative treatment group.

While the findings underscored in the study are palpably valuable, it's important to underscore that this research didn’t integrate psychotherapy as part of the delivery for Ketamine, an element often deemed instrumental in amplifying its efficacy. Ketamine, when paired with psychotherapy, frequently paves the way for a synergistic effect, enhancing treatment outcomes, particularly in mental health and well-being.


Moreover, while the study elucidated the merits of nasal delivery of esketamine, it's helpful to acknowledge the existence and potential of alternative delivery methods. The nasal approach is a pricier option of available treatment modes. However, it’s worth noting that in some instances, these costs may be mitigated through insurance provisions, softening the financial impact upon the individual receiving treatment.


Navigating through the myriad of treatment options in the mental health space demands a thorough, multi-faceted examination. While the findings from the study presented at Psych Congress 2023 undeniably carve out a niche of interest and promise within the TRD treatment landscape, it also sparks further curiosity. It opens doors to future research that interweaves psychotherapy and explores varied ketamine delivery methods, each with its own clinical and economic implications, all in pursuit of architecting a robust, accessible, and effective treatment paradigm for TRD.


I've seen transformative change when using ketamine with psychotherapy in my practice. I'm excited about emerging research that continues to demonstrate the results I see in my office.

10 views0 comments
bottom of page